Journal
VACCINE
Volume 27, Issue -, Pages D69-D72Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.07.046
Keywords
Rift Valley fever virus; MP-12; Vaccine
Categories
Funding
- NIAID NIH HHS [U54 AI057156, U54 AI057156-06] Funding Source: Medline
Ask authors/readers for more resources
Rift Valley fever virus (RVFV), which belongs to the genus Phlebovirus, family Bunyaviridae, is a negative-stranded RNA virus carrying a tripartite RNA genome. RVFV is transmitted by mosquitoes and causes large outbreaks among ruminants and humans in Africa and the Arabian Peninsula. Human patients develop an acute febrile illness, followed by a fatal hemorrhagic fever, encephalitis or ocular diseases, whereas ruminants experience abortions during outbreak. Effective vaccination of both humans and ruminants is the best approach to control Rift Valley fever. This article summarizes the development of inactivated RVFV vaccine, live attenuated vaccine, and other new generation vaccines. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available